Deferiprone in iron overload

Jayesh Mehta*, Seema Singhal, B. C. Mehta, D. Adhikari, A. V. Hoffbrand, B. Wonke, D. G. Nathan

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

7 Scopus citations


To the Editor: Olivieri et al. (April 6 issue)1 are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.25 Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.2 We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies.

Original languageEnglish (US)
Pages (from-to)597-599
Number of pages3
JournalNew England Journal of Medicine
Issue number9
StatePublished - Aug 31 1995

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Deferiprone in iron overload'. Together they form a unique fingerprint.

Cite this